Rectal and colon cancer: Not just a different anatomic site.
Groningen, Netherlands. In Cancer Treat Rev, 28 Jul 2015
Moreover, they harbor a different composition of drug targets, such as v-raf murine sarcoma viral oncogene homolog B (BRAF), which is preferentially mutated in proximal colon cancers, and the epidermal growth factor receptor (EGFR), which is prevalently amplified or overexpressed in distal colorectal cancers.
Genomic Classification of Cutaneous Melanoma.
In Cell, 18 Jul 2015
We establish a framework for genomic classification into one of four subtypes based on the pattern of the most prevalent significantly mutated genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type).
BRAF inhibitors: the current and the future.
New York City, United States. In Curr Opin Pharmacol, 10 Jul 2015
UNASSIGNED: The introduction of BRAF inhibitors (BRAFi), vemurafenib and dabrafenib, revolutionized BRAFV600-mutated metastatic melanoma treatment with improved response rate and overall survival compared to standard chemotherapy.
Different treatment strategies and molecular features between right-sided and left-sided colon cancers.
Hangzhou, China. In World J Gastroenterol, 07 Jul 2015
With respect to carcinogenesis mechanisms, RCC is associated with known gene types, such as MMR, KRAS, BRAF, and miRNA-31, while LCC is associated with CIN, p53, NRAS, miRNA-146a, miRNA-147b, and miRNA-1288.
Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Lausanne, Switzerland. In Cancer Treat Rev, 04 Jul 2015
A greater understanding of the epidemiology and biology of disease has underpinned the development of newer therapies, including six agents that have been approved in the EU, US and/or Japan: a cytotoxic T-lymphocyte antigen-4 inhibitor (ipilimumab), two programmed cell death-1 receptor inhibitors (nivolumab and pembrolizumab), two BRAF inhibitors (vemurafenib and dabrafenib) and a MEK inhibitor (trametinib).